FA
GYRE icon

Financial Advantage’s Gyre Therapeutics GYRE Stock Holding History

Financial Advantage’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2
Closed -$8K – 235
2013
Q3 		$8K Hold
2
– – 0.01% 150
2013
Q2 		$6K Buy
+2
New +$7.61K 0.01% 164

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Financial Advantage's GYRE Position: Q4 2013 in Review

Financial Advantage sold out of Gyre Therapeutics (GYRE) in Q4 2013, closing a stake of 2 shares — an estimated $8K sold.

Financial Advantage first reported a position in GYRE in Q2 2013 and held it in 2 quarters. The position peaked at $8K in Q3 2013. 74 funds tracked by Wall St. Rank hold GYRE as of Q4 2013.

  • Financial Advantage reported no remaining Gyre Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Financial Advantage sold 2 Gyre Therapeutics shares in Q4 2013, an estimated $8K.
  • Financial Advantage first reported a position in Gyre Therapeutics in Q2 2013 and held it in 2 quarters.
  • Financial Advantage's Gyre Therapeutics position peaked at $8K in Q3 2013.
  • 74 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2013.

Based on Financial Advantage's 13F filing for Q4 2013, filed 12 Feb 2014.